This is also confirmed by research by Malpic et al. [45], which showed that CD30 and PD-1/PD-L1 expression appear as potentially unfavorable but targetable biomarkers in EBV-positive diffuse large B-cell lymphoma, and as indicated by the Ozturk study in the course of classical Hodgkin lymphoma [46]. The gene discussed is PDCD1; the disease is Hodgkins lymphoma.